Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort
Purpose Pancreatic cancer is one of the most fatal malignancies and the fourth leading cause of cancer-related mortality in the USA. Most clinical trials involving pancreatic adenocarcinoma (PAC) patients exclude subjects with a prior malignancy because of the possible effect of prior malignancies o...
Gespeichert in:
| Veröffentlicht in: | Journal of gastrointestinal cancer 2019-12, Vol.50 (4), p.794-800 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 800 |
|---|---|
| container_issue | 4 |
| container_start_page | 794 |
| container_title | Journal of gastrointestinal cancer |
| container_volume | 50 |
| creator | Al-Husseini, Muneer J. Saad, Anas M. Turk, Tarek Tabash, Mohamed A. Abdel-Rahman, Omar |
| description | Purpose
Pancreatic cancer is one of the most fatal malignancies and the fourth leading cause of cancer-related mortality in the USA. Most clinical trials involving pancreatic adenocarcinoma (PAC) patients exclude subjects with a prior malignancy because of the possible effect of prior malignancies on survival. However, no data in the medical literature support this assumption. In this paper, we aim to study the impact of having a prior malignancy on the survival outcomes of stage IV PAC.
Methods
We used the surveillance, epidemiology, and end results database to review patients with stage IV PAC diagnosed between 1973 and 2014. We calculated overall and pancreatic cancer-specific survival of these patients using unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models.
Results
We reviewed 66,874 stage IV PAC patients, of which 4942 had a prior malignancy. Kaplan-Meier and Cox models showed that a history of prior malignancy did not cause significant difference in overall survival (HR = 0.938, 95%CI = 0.880–1.000,
p
= .052). However, a prior malignancy was associated with a better pancreatic cancer-specific survival (HR = 0.855, 95% CI = 0.796–0.918,
p
|
| doi_str_mv | 10.1007/s12029-018-0158-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2088295221</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2088295221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-9fd6f69a309485a12aa28aa71c64528579978809191c29f9ae9c7e7b67162aef3</originalsourceid><addsrcrecordid>eNp9kE1PAjEURRujEfz4AW5Ml25G-zpfrTskqCQaiKjb5lE6MGRmiu0Mif_eEtCli6ZNeu7Ne4eQK2C3wFh-54EzLiMGIpxURMkR6YNMIMqyODv-e3PRI2ferxnLkhTglPRiBixNedwnq3G9Qd1SW9CpK62jr1iVywYb_U1tQ2ed25ZbrOika7Wtjd-BsxaXho4_6TRgzmBbajpYmMZqdLpsbI33dDYavUUP6M2CDu3KuvaCnBRYeXN5uM_Jx-PoffgcvUyexsPBS6TjJGkjWSyyIpMYM5mIFIEjcoGYgw6zc5HmUuZCMAkSNJeFRCN1bvJ5lkPG0RTxObnZ926c_eqMb1Vdem2qChtjO684E4LLlHMIKOxR7az3zhRq48oa3bcCpnaC1V6wCoLVTrBKQub6UN_Na7P4S_waDQDfAz58NUvj1Np2rgkr_9P6A6o_hI0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2088295221</pqid></control><display><type>article</type><title>Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Al-Husseini, Muneer J. ; Saad, Anas M. ; Turk, Tarek ; Tabash, Mohamed A. ; Abdel-Rahman, Omar</creator><creatorcontrib>Al-Husseini, Muneer J. ; Saad, Anas M. ; Turk, Tarek ; Tabash, Mohamed A. ; Abdel-Rahman, Omar</creatorcontrib><description>Purpose
Pancreatic cancer is one of the most fatal malignancies and the fourth leading cause of cancer-related mortality in the USA. Most clinical trials involving pancreatic adenocarcinoma (PAC) patients exclude subjects with a prior malignancy because of the possible effect of prior malignancies on survival. However, no data in the medical literature support this assumption. In this paper, we aim to study the impact of having a prior malignancy on the survival outcomes of stage IV PAC.
Methods
We used the surveillance, epidemiology, and end results database to review patients with stage IV PAC diagnosed between 1973 and 2014. We calculated overall and pancreatic cancer-specific survival of these patients using unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models.
Results
We reviewed 66,874 stage IV PAC patients, of which 4942 had a prior malignancy. Kaplan-Meier and Cox models showed that a history of prior malignancy did not cause significant difference in overall survival (HR = 0.938, 95%CI = 0.880–1.000,
p
= .052). However, a prior malignancy was associated with a better pancreatic cancer-specific survival (HR = 0.855, 95% CI = 0.796–0.918,
p
< .001).
Conclusion
A prior malignancy before stage IV PAC was not associated with worse survival outcomes. Researchers should take these results into consideration when including/excluding patients to improve the generalizability and accuracy of their results.</description><identifier>ISSN: 1941-6628</identifier><identifier>EISSN: 1941-6636</identifier><identifier>DOI: 10.1007/s12029-018-0158-4</identifier><identifier>PMID: 30105523</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - therapy ; Adult ; Aged ; Cancer Research ; Clinical Trials as Topic - methods ; Female ; Follow-Up Studies ; Gastroenterology ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Neoplasms, Second Primary - microbiology ; Neoplasms, Second Primary - pathology ; Neoplasms, Second Primary - therapy ; Oncology ; Original Research ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; Patient Selection ; Radiotherapy ; SEER Program - statistics & numerical data ; Treatment Outcome</subject><ispartof>Journal of gastrointestinal cancer, 2019-12, Vol.50 (4), p.794-800</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-9fd6f69a309485a12aa28aa71c64528579978809191c29f9ae9c7e7b67162aef3</citedby><cites>FETCH-LOGICAL-c344t-9fd6f69a309485a12aa28aa71c64528579978809191c29f9ae9c7e7b67162aef3</cites><orcidid>0000-0003-0101-0131</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12029-018-0158-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12029-018-0158-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30105523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Husseini, Muneer J.</creatorcontrib><creatorcontrib>Saad, Anas M.</creatorcontrib><creatorcontrib>Turk, Tarek</creatorcontrib><creatorcontrib>Tabash, Mohamed A.</creatorcontrib><creatorcontrib>Abdel-Rahman, Omar</creatorcontrib><title>Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort</title><title>Journal of gastrointestinal cancer</title><addtitle>J Gastrointest Canc</addtitle><addtitle>J Gastrointest Cancer</addtitle><description>Purpose
Pancreatic cancer is one of the most fatal malignancies and the fourth leading cause of cancer-related mortality in the USA. Most clinical trials involving pancreatic adenocarcinoma (PAC) patients exclude subjects with a prior malignancy because of the possible effect of prior malignancies on survival. However, no data in the medical literature support this assumption. In this paper, we aim to study the impact of having a prior malignancy on the survival outcomes of stage IV PAC.
Methods
We used the surveillance, epidemiology, and end results database to review patients with stage IV PAC diagnosed between 1973 and 2014. We calculated overall and pancreatic cancer-specific survival of these patients using unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models.
Results
We reviewed 66,874 stage IV PAC patients, of which 4942 had a prior malignancy. Kaplan-Meier and Cox models showed that a history of prior malignancy did not cause significant difference in overall survival (HR = 0.938, 95%CI = 0.880–1.000,
p
= .052). However, a prior malignancy was associated with a better pancreatic cancer-specific survival (HR = 0.855, 95% CI = 0.796–0.918,
p
< .001).
Conclusion
A prior malignancy before stage IV PAC was not associated with worse survival outcomes. Researchers should take these results into consideration when including/excluding patients to improve the generalizability and accuracy of their results.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Cancer Research</subject><subject>Clinical Trials as Topic - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Second Primary - microbiology</subject><subject>Neoplasms, Second Primary - pathology</subject><subject>Neoplasms, Second Primary - therapy</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Patient Selection</subject><subject>Radiotherapy</subject><subject>SEER Program - statistics & numerical data</subject><subject>Treatment Outcome</subject><issn>1941-6628</issn><issn>1941-6636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PAjEURRujEfz4AW5Ml25G-zpfrTskqCQaiKjb5lE6MGRmiu0Mif_eEtCli6ZNeu7Ne4eQK2C3wFh-54EzLiMGIpxURMkR6YNMIMqyODv-e3PRI2ferxnLkhTglPRiBixNedwnq3G9Qd1SW9CpK62jr1iVywYb_U1tQ2ed25ZbrOika7Wtjd-BsxaXho4_6TRgzmBbajpYmMZqdLpsbI33dDYavUUP6M2CDu3KuvaCnBRYeXN5uM_Jx-PoffgcvUyexsPBS6TjJGkjWSyyIpMYM5mIFIEjcoGYgw6zc5HmUuZCMAkSNJeFRCN1bvJ5lkPG0RTxObnZ926c_eqMb1Vdem2qChtjO684E4LLlHMIKOxR7az3zhRq48oa3bcCpnaC1V6wCoLVTrBKQub6UN_Na7P4S_waDQDfAz58NUvj1Np2rgkr_9P6A6o_hI0</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Al-Husseini, Muneer J.</creator><creator>Saad, Anas M.</creator><creator>Turk, Tarek</creator><creator>Tabash, Mohamed A.</creator><creator>Abdel-Rahman, Omar</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0101-0131</orcidid></search><sort><creationdate>20191201</creationdate><title>Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort</title><author>Al-Husseini, Muneer J. ; Saad, Anas M. ; Turk, Tarek ; Tabash, Mohamed A. ; Abdel-Rahman, Omar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-9fd6f69a309485a12aa28aa71c64528579978809191c29f9ae9c7e7b67162aef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Cancer Research</topic><topic>Clinical Trials as Topic - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Second Primary - microbiology</topic><topic>Neoplasms, Second Primary - pathology</topic><topic>Neoplasms, Second Primary - therapy</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Patient Selection</topic><topic>Radiotherapy</topic><topic>SEER Program - statistics & numerical data</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Husseini, Muneer J.</creatorcontrib><creatorcontrib>Saad, Anas M.</creatorcontrib><creatorcontrib>Turk, Tarek</creatorcontrib><creatorcontrib>Tabash, Mohamed A.</creatorcontrib><creatorcontrib>Abdel-Rahman, Omar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastrointestinal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Husseini, Muneer J.</au><au>Saad, Anas M.</au><au>Turk, Tarek</au><au>Tabash, Mohamed A.</au><au>Abdel-Rahman, Omar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort</atitle><jtitle>Journal of gastrointestinal cancer</jtitle><stitle>J Gastrointest Canc</stitle><addtitle>J Gastrointest Cancer</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>50</volume><issue>4</issue><spage>794</spage><epage>800</epage><pages>794-800</pages><issn>1941-6628</issn><eissn>1941-6636</eissn><abstract>Purpose
Pancreatic cancer is one of the most fatal malignancies and the fourth leading cause of cancer-related mortality in the USA. Most clinical trials involving pancreatic adenocarcinoma (PAC) patients exclude subjects with a prior malignancy because of the possible effect of prior malignancies on survival. However, no data in the medical literature support this assumption. In this paper, we aim to study the impact of having a prior malignancy on the survival outcomes of stage IV PAC.
Methods
We used the surveillance, epidemiology, and end results database to review patients with stage IV PAC diagnosed between 1973 and 2014. We calculated overall and pancreatic cancer-specific survival of these patients using unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models.
Results
We reviewed 66,874 stage IV PAC patients, of which 4942 had a prior malignancy. Kaplan-Meier and Cox models showed that a history of prior malignancy did not cause significant difference in overall survival (HR = 0.938, 95%CI = 0.880–1.000,
p
= .052). However, a prior malignancy was associated with a better pancreatic cancer-specific survival (HR = 0.855, 95% CI = 0.796–0.918,
p
< .001).
Conclusion
A prior malignancy before stage IV PAC was not associated with worse survival outcomes. Researchers should take these results into consideration when including/excluding patients to improve the generalizability and accuracy of their results.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30105523</pmid><doi>10.1007/s12029-018-0158-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0101-0131</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-6628 |
| ispartof | Journal of gastrointestinal cancer, 2019-12, Vol.50 (4), p.794-800 |
| issn | 1941-6628 1941-6636 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2088295221 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - therapy Adult Aged Cancer Research Clinical Trials as Topic - methods Female Follow-Up Studies Gastroenterology Humans Internal Medicine Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Neoplasms, Second Primary - microbiology Neoplasms, Second Primary - pathology Neoplasms, Second Primary - therapy Oncology Original Research Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Patient Selection Radiotherapy SEER Program - statistics & numerical data Treatment Outcome |
| title | Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A17%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Prior%20Malignancy%20on%20Survival%20Outcomes%20of%20Stage%20IV%20Pancreatic%20Adenocarcinoma:%20SEER-Based%20Cohort&rft.jtitle=Journal%20of%20gastrointestinal%20cancer&rft.au=Al-Husseini,%20Muneer%20J.&rft.date=2019-12-01&rft.volume=50&rft.issue=4&rft.spage=794&rft.epage=800&rft.pages=794-800&rft.issn=1941-6628&rft.eissn=1941-6636&rft_id=info:doi/10.1007/s12029-018-0158-4&rft_dat=%3Cproquest_cross%3E2088295221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2088295221&rft_id=info:pmid/30105523&rfr_iscdi=true |